Cohance Lifesciences Appoints Dr. Kuber Jagdale as CTO & Executive Director
#PharmaIndustry #OperationalExcellence #LeadershipUpdates #LifeSciences #LeadershipAnnouncement #ExecutiveAppointment #PharmaLeadership #CohanceLifesciences #ChiefTechnicalOfficer
Nov 2026 : Cohance Lifesciences has recently appointed Dr. Kuber Jagdale as its Chief Technical Officer (CTO) and Executive Director. A seasoned heavyweight in the pharmaceutical industry, Dr. Jagdale steps into the leadership role to help steer the company’s global technical strategy, scale its operational design, and advance its unifying ‘One Cohance’ operating philosophy across its manufacturing network.
With nearly four decades of hands-on leadership, Dr. Jagdale brings a wealth of expertise spanning active pharmaceutical ingredient (API) manufacturing, supply chain management, plant design, technology transfer, and Environmental, Health, and Safety (EHS) implementation. At Cohance, his immediate focus will be on embedding operational excellence, driving standardization, and building a resilient, future-ready infrastructure as the organization accelerates its expansion in the global life sciences space.
Dr. Jagdale’s distinguished career spans over 39 years across top-tier pharmaceutical organizations. He spent 32 transformative years at Cipla, ascending through key manufacturing roles from Production Manager to Senior Vice President of Technical Operations. He later served as Chief Operating Officer at Sekhmet Pharmaventures and most recently served as President at Emcure Pharmaceuticals Limited. He began his career at EPIC Pvt Ltd.
Dr. Jagdale earned his B.Sc. (Tech) in Applied Drugs from the University of Mumbai and completed executive leadership training at IIM Bangalore (IIMBx). To deepen his technical expertise, he completed a specialized Flow Chemistry workshop at the Massachusetts Institute of Technology (MIT), and later earned a PhD in Pharmaceutical Sciences from the Kennedy University of Baptist.
NEWSLETTER
TRENDING ON PRO MFG
MORE FROM THE SECTION
